South Africa's BEAT Tuberculosis study improves drug-resistant TB treatment

Findings from South Africa's BEAT Tuberculosis study, published in the New England Journal of Medicine, show a new six-month regimen cures 90 percent of drug-resistant TB cases.

The clinical study began in Gqeberha in the Eastern Cape to test the safety and effectiveness of a shortened treatment for drug-resistant tuberculosis.

Dr Francesca Conradie of the Clinical Health Research Unit at Wits University described the change. She said previous regimens lasted 18 months with daily injections for the first six months, cured only half the patients, and caused side effects such as hearing loss, nausea and vomiting.

The new approach lasts six months and achieves a 90 percent cure rate, according to the study results released this week.

Labaran da ke da alaƙa

South Africa has started rolling out the twice-yearly HIV prevention injection lenacapavir, though success depends on managing interactions with common tuberculosis medicines.

An Ruwaito ta hanyar AI

A new combination pill containing bictegravir and lenacapavir shows promise for people with HIV who require complex regimens. The phase three ARTISTRY 1 study found it performed as well as existing multi-pill options. Experts note its impact in South Africa will likely remain limited.

An experimental mRNA vaccine has demonstrated effectiveness against three strains of Ebola virus in rodent tests. The vaccine targets Zaire, Sudan and Bundibugyo viruses. Researchers developed it amid an ongoing outbreak of Bundibugyo virus in Africa.

An Ruwaito ta hanyar AI

A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi